Hyaluronic Acid and Stem Cell Sequencing for Cartilage Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cartilage damage-associated diseases using hyaluronic acid and mesenchymal stem cells face challenges such as adverse effects and inconvenience due to high concentrations, necessitating an optimized treatment method.
Innovation Solution
Administering hyaluronic acid followed by umbilical cord blood-derived mesenchymal stem cells to treat cartilage damage-associated diseases, optimizing the sequence to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If hyaluronic acid and mesenchymal stem cells are administered in admixture, then the treatment method is simple, but the therapeutic effect is insufficient
Solution Approach 1:
The patent divides the treatment into two separate administration steps: first administering hyaluronic acid, then administering mesenchymal stem cells. This segmentation allows each component to perform its optimal function independently, resolving the contradiction between treatment simplicity and therapeutic effectiveness.
Solution Approach 2:
The patent applies preliminary action by administering hyaluronic acid before mesenchymal stem cells. The hyaluronic acid prepares the joint environment first, creating favorable conditions for subsequent stem cell therapy, thereby enhancing overall therapeutic effect while maintaining a relatively simple two-step process.
2Reliability
If hyaluronic acid of concentration 4% is used, then the therapeutic effect is enhanced, but the injection formulation becomes inconvenient and causes adverse effects
Solution Approach 1:
The patent changes the concentration parameter of hyaluronic acid from the conventional 4% to a lower range (0.1%-2%), making the injection formulation more convenient and reducing adverse effects. The therapeutic effect is maintained through the optimized sequential administration protocol rather than relying solely on high concentration.
Solution Approach 2:
The patent uses mesenchymal stem cells as an intermediary that enhances the therapeutic effect without requiring high concentrations of hyaluronic acid. The stem cells work synergistically with the lower concentration hyaluronic acid to achieve improved cartilage regeneration while avoiding the inconveniences of high concentration formulations.
3Reliability
If hyaluronic acid and mesenchymal stem cells are administered sequentially, then the therapeutic effect is improved, but the treatment process becomes more complex
Solution Approach 1:
The patent segments the treatment into two distinct but simple steps: first hyaluronic acid administration, then mesenchymal stem cell administration. This segmentation improves therapeutic effect while keeping each individual step simple and well-established, minimizing overall process complexity.
Solution Approach 2:
The sequential administration follows a preliminary action principle where hyaluronic acid is given first to prepare the joint environment, followed by stem cell injection. This logical sequence enhances efficacy without requiring complex coordination, as each step builds naturally on the previous one.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention relates to a pharmaceutical composition comprising hyaluronic acid and mesenchymal stem cells for treating cartilage damage-associated diseases. Compared to when hyaluronic acid and mesenchymal stem cells are administered as a mixture, administering mesenchymal stem cells after first administering hyaluronic acid, according to the present invention, may exhibit superior effects in alleviating disease symptoms in joint tissues affected by arthritis and also decrease the load on knees due to body weight. Accordingly, the pharmaceutical composition of the present invention may be beneficially used in the treatment of cartilage damage-associated diseases.